Literature DB >> 17390352

Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI.

C C Quarles1, K M Schmainda.   

Abstract

To investigate the influence of anti-angiogenic agents on tumor perfusion, we employed a dynamic susceptibility contrast (DSC)-MRI method that utilizes a simultaneous gradient-echo (GE) and spin-echo (SE) imaging sequence to derive perfusion parameters (blood flow, blood volume, and mean transit time (MTT)). These parameters are sensitive to both the total vasculature (from the GE data) and the microvasculature (from the SE data), and can also provide a measure of the mean vessel diameter (mVD). This approach was used to evaluate the response of a 9L rat brain tumor model to 20 mg/kg and 40 mg/kg of the anti-angiogenic agent SU11657. The 20-mg/kg dose significantly decreased mVD by 29.9% (P = 0.02). The 40-mg/kg dose significantly decreased mVD by 30.4% (P = 0.0007), SE blood volume by 31.8% (P = 0.03), GE and SE MTT by 46.9% (P = 0.03) and 62.0% (P = 0.0005), and increased GE and SE blood flow by 36.6% (P = 0.04) and 52.6% (P = 0.02). These findings demonstrate that DSC-MRI perfusion methods can play a key role in the noninvasive evaluation of morphological and functional changes in tumor vasculature in response to therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17390352     DOI: 10.1002/mrm.21193

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  15 in total

Review 1.  Translating preclinical MRI methods to clinical oncology.

Authors:  David A Hormuth; Anna G Sorace; John Virostko; Richard G Abramson; Zaver M Bhujwalla; Pedro Enriquez-Navas; Robert Gillies; John D Hazle; Ralph P Mason; C Chad Quarles; Jared A Weis; Jennifer G Whisenant; Junzhong Xu; Thomas E Yankeelov
Journal:  J Magn Reson Imaging       Date:  2019-03-29       Impact factor: 4.813

Review 2.  Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.

Authors:  Kyrre E Emblem; Christian T Farrar; Elizabeth R Gerstner; Tracy T Batchelor; Ronald J H Borra; Bruce R Rosen; A Gregory Sorensen; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2014-08-12       Impact factor: 66.675

3.  HiSStology: high spectral and spatial resolution magnetic resonance imaging detection of vasculature validated by histology and micro-computed tomography.

Authors:  Chad R Haney; Charles A Pelizzari; Sean Foxley; Marta A Zamora; Devkumar Mustafi; Maria Tretiakova; Shihong Li; Xiaobing Fan; Gregory S Karczmar
Journal:  Mol Imaging       Date:  2011-03-01       Impact factor: 4.488

4.  T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients.

Authors:  Kyrre E Emblem; Atle Bjornerud; Kim Mouridsen; Ronald J H Borra; Tracy T Batchelor; Rakesh K Jain; A Gregory Sorensen
Journal:  J Cereb Blood Flow Metab       Date:  2011-04-20       Impact factor: 6.200

5.  High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI.

Authors:  M M Pike; C N Stoops; C P Langford; N S Akella; L B Nabors; G Y Gillespie
Journal:  Magn Reson Med       Date:  2009-03       Impact factor: 4.668

6.  Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.

Authors:  Peter S LaViolette; Alex D Cohen; Melissa A Prah; Scott D Rand; Jennifer Connelly; Mark G Malkin; Wade M Mueller; Kathleen M Schmainda
Journal:  Neuro Oncol       Date:  2013-02-03       Impact factor: 12.300

Review 7.  Advanced techniques using contrast media in neuroimaging.

Authors:  Jean-Christophe Ferré; Mark S Shiroishi; Meng Law
Journal:  Magn Reson Imaging Clin N Am       Date:  2012-09-25       Impact factor: 2.266

8.  MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model.

Authors:  Samuel Valable; Dauphou Eddi; Jean-Marc Constans; Jean-Sébastien Guillamo; Myriam Bernaudin; Simon Roussel; Edwige Petit
Journal:  Neuro Oncol       Date:  2009-01-23       Impact factor: 12.300

9.  Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model.

Authors:  Xianhuo Wang; Xingmei Duan; Guangli Yang; Xiaoyan Zhang; Linyu Deng; Hao Zheng; Chongyang Deng; Jiaolin Wen; Ning Wang; Cheng Peng; Xia Zhao; Yuquan Wei; Lijuan Chen
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  Multimodality imaging of abnormal vascular perfusion and morphology in preclinical 9L gliosarcoma model.

Authors:  Moses M Darpolor; Robert C Molthen; Kathleen M Schmainda
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.